ITGAX and neoplasm: This was further confirmed in an ex-vivo DC suppression assay, where influence of MIP treated CD11c+ DCs (isolated from tumor draining lymph node) on the capacity of other immunocompetent DCs (tumor antigen pulsed BMDCs) to present tumor antigens to tumor specific T cells was determined.